Patents by Inventor Carla Christina Schrier
Carla Christina Schrier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240041760Abstract: The invention pertains to a vaccine comprising non-live antigen of a poultry pathogen and a mucoadhesive adjuvant, for use in boosting an immune response in a poultry animal directed against the poultry pathogen by administering the vaccine mucosally to the poultry animal. The invention also pertains to a vaccine comprising a liquid pharmaceutically acceptable carrier, a non-live antigen of a poultry pathogen and a mucoadhesive adjuvant, as well as a method of boosting an immune response in a poultry animal, which immune response is directed against a poultry pathogen, by administering a vaccine mucosally to the poultry animal, the vaccine comprising a non-live antigen of the said poultry pathogen and a mucoadhesive adjuvant.Type: ApplicationFiled: February 7, 2021Publication date: February 8, 2024Applicant: Intervet Inc.Inventors: Willem Pieter Cornelis Pulskens, Paul Vermeij, Theodorus Jansen, Wilhelmus Gerardus Johannes Degen, Carla Christina Schrier
-
Patent number: 10954491Abstract: The present invention relates to a novel porcine pestivirus, to proteins of the virus and to vaccines based upon the virus and proteins thereof. The invention also relates to DNA fragments comprising a gene of the virus and to DNA vaccines based upon genes of the virus. Furthermore the invention relates to antibodies that are reactive with the novel virus and to diagnostic tests for the detection of the virus or antibodies against the virus.Type: GrantFiled: December 18, 2015Date of Patent: March 23, 2021Assignee: Intervet Inc.Inventors: Ad de Groof, Lars Guelen, Carla Christina Schrier, Martin Deijs, Cornelia Maria van der Hoek
-
Patent number: 10512685Abstract: The present invention relates to a vaccine comprising Open Reading Frame 2 (ORF2) protein of Swine Hepatitis E virus (HEV) and a pharmaceutically acceptable carrier, for use in the protection of anti-HEV MDA-positive piglets against HEV fecal shedding.Type: GrantFiled: May 24, 2017Date of Patent: December 24, 2019Assignee: Intervet Inc.Inventors: Paul Vermeij, Ad Groof De, Carla Christina Schrier, Wannes Vogels
-
Patent number: 10398773Abstract: The present invention relates to a novel porcine parvovirus, to proteins of the virus and to vaccines based upon the virus and proteins thereof. The invention also relates to DNA fragments comprising a gene of the virus and to DNA vaccines based upon genes of the virus. Further the invention relates to antibodies that are reactive with the novel virus and to diagnostic tests for the detection of the virus or antibodies against the virus.Type: GrantFiled: April 16, 2015Date of Patent: September 3, 2019Assignee: Intervet Inc.Inventors: Lars Guelen, Ad de Groof, Carla Christina Schrier, Martin Deijs, Cornelia Maria Hoek Van Der
-
Publication number: 20190151442Abstract: The present invention relates to a vaccine comprising Open Reading Frame 2 (ORF2) protein of Swine Hepatitis E virus (HEV) and a pharmaceutically acceptable carrier, for use in the protection of anti-HEV MDA-positive piglets against HEV fecal shedding.Type: ApplicationFiled: May 24, 2017Publication date: May 23, 2019Applicant: Intervet Inc.Inventors: Paul Vermeij, Ad Groof De, Carla Christina Schrier, Wannes Vogels
-
Patent number: 10166282Abstract: The present invention relates to immortalized porcine alveolar macrophages (PAMs), to cell cultures comprising such PAMs, to methods for the immortalization of PAMs, to methods of replicating PRRS virus on immortalized PAMs and to methods for the preparation of vaccines comprising PRRSV.Type: GrantFiled: December 8, 2017Date of Patent: January 1, 2019Assignee: Intervet Inc.Inventors: Jaap Kool, Carla Christina Schrier
-
Publication number: 20180161417Abstract: The present invention relates to immortalized porcine alveolar macrophages (PAMs), to cell cultures comprising such PAMs, to methods for the immortalization of PAMs, to methods of replicating PRRS virus on immortalised PAMs and to methods for the preparation of vaccines comprising PRRSV.Type: ApplicationFiled: December 8, 2017Publication date: June 14, 2018Applicant: Intervet Inc.Inventors: Jaap Kool, Carla Christina Schrier
-
Patent number: 9872896Abstract: The present invention relates to immortalized porcine alveolar macrophages (PAMs), to cell cultures comprising such PAMs, to methods for the immortalization of PAMs, to methods of replicating PRRS virus on immortalized PAMs and to methods for the preparation of vaccines comprising PRRSV.Type: GrantFiled: December 11, 2014Date of Patent: January 23, 2018Assignee: Intervet Inc.Inventors: Jaap Kool, Carla Christina Schrier
-
Publication number: 20170342387Abstract: The present invention relates to a novel porcine pestivirus, to proteins of the virus and to vaccines based upon the virus and proteins thereof. The invention also relates to DNA fragments comprising a gene of the virus and to DNA vaccines based upon genes of the virus. Furthermore the invention relates to antibodies that are reactive with the novel virus and to diagnostic tests for the detection of the virus or antibodies against the virus.Type: ApplicationFiled: December 18, 2015Publication date: November 30, 2017Applicant: Intervet Inc.Inventors: Ad de Groof, Lars Guelen, Carla Christina Schrier, Martin Deijs, Cornelia Maria van der Hoek
-
Patent number: 9757449Abstract: The addition of an oligodeoxynucleotide that is an avian TLR21 agonist, to an avian Herpesvirus vector vaccine, provides an acceleration of the immune response against the antigen that is expressed and delivered by the Herpesvirus vector.Type: GrantFiled: July 25, 2014Date of Patent: September 12, 2017Assignee: Intervet Inc.Inventors: Carla Christina Schrier, Wilhelmus Gerardus Johannes Degen
-
Patent number: 9597390Abstract: The present invention relates to Infectious bronchitis virus (IBV) spike protein or a fragment thereof comprising a receptor-binding domain, wherein said spike protein or said fragment thereof is C-terminally fused to a trimerisation or tetramerisation domain. Such proteins form trimer or tetramer structures and as such they mimic the natural context of the spike protein. The present invention further relates to subunit vaccines comprising such a protein, to DNA molecules encoding such proteins, to plasmids comprising such DNA molecules, to avian live recombinant carrier viruses (LRCV's) comprising such DNA molecules or plasmids, to vaccines comprising such DNA molecules, plasmids and LRCV's and to combination vaccines comprising an IBV spike protein, DNA molecules, plasmids or LRCV's encoding such a protein, and another IBV vaccine capable of inducing protection against another IBV serotype and/or a vaccine capable of inducing protection against another avian pathogen.Type: GrantFiled: March 1, 2012Date of Patent: March 21, 2017Assignees: Utrech University, Intervet Inc.Inventors: Hélène Verheije, Carla Christina Schrier
-
Publication number: 20170056492Abstract: The present invention relates to a novel porcine parvovirus, to proteins of the virus and to vaccines based upon the virus and proteins thereof. The invention also relates to DNA fragments comprising a gene of the virus and to DNA vaccines based upon genes of the virus. Further the invention relates to antibodies that are reactive with the novel virus and to diagnostic tests for the detection of the virus or antibodies against the virus.Type: ApplicationFiled: April 16, 2015Publication date: March 2, 2017Applicant: Intervet Inc.Inventors: Lars Guelen, Ad Groof, Carla Christina Schrier, Martin Deijs, Cornelia Maria Hoek Van Der
-
Publication number: 20160303220Abstract: The present invention relates to immortalized porcine alveolar macrophages (PAMs), to cell cultures comprising such PAMs, to methods for the immortalization of PAMs, to methods of replicating PRRS virus on immortalised PAMs and to methods for the preparation of vaccines comprising PRRSV.Type: ApplicationFiled: December 11, 2014Publication date: October 20, 2016Applicant: Intervet Inc.Inventors: Jaap Kool, Carla Christina Schrier
-
Patent number: 9364531Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease, to methods for the detection of such oligodeoxynucleotides and to cells to be used in these method.Type: GrantFiled: December 29, 2011Date of Patent: June 14, 2016Assignee: Intervet Inc.Inventors: Carla Christina Schrier, Thomas Simon Ilg
-
Publication number: 20160158347Abstract: The addition of an oligodeoxynucleotide that is an avian TLR21 agonist, to an avian Herpesvirus vector vaccine, provides an acceleration of the immune response against the antigen that is expressed and delivered by the Herpesvirus vector.Type: ApplicationFiled: July 25, 2014Publication date: June 9, 2016Applicant: Intervet Inc.Inventors: Carla Christina Schrier, Wilhelmus Gerardus Johannes Degen
-
Patent number: 9359602Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease, to methods for the detection of such oligodeoxynucleotides and to cells to be used in these methods.Type: GrantFiled: May 25, 2012Date of Patent: June 7, 2016Assignee: Intervet Inc.Inventors: Carla Christina Schrier, Simon Ilg
-
Publication number: 20160136197Abstract: The present invention relates to pharmaceutical compositions comprising an immunostimulatory amount of at least two immunopotentiators, wherein a first immunopotentiator is a non-methylated cytidyl guanosyl oligodeoxynucleotide (CpG ODN) and a second immunopotentiator is 3?,5?-cyclic diguanylic acid (c-di-GMP), and a pharmaceutically acceptable carrier. The invention also relates to the use of such pharmaceutical compositions for the induction of an immune response against tumor-specific antigens. Also the invention relates to their use in in situ tumor-destruction therapy and to such pharmaceutical compositions for use in the treatment of a mammal suffering from cancer.Type: ApplicationFiled: June 13, 2014Publication date: May 19, 2016Inventors: Carla Christina Schrier, Martijn BROK DEN, Gosse Adema
-
Patent number: 9315814Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease and to methods for the detection of such oligodeoxynucleotides.Type: GrantFiled: May 25, 2012Date of Patent: April 19, 2016Assignee: Intervet Inc.Inventors: Carla Christina Schrier, Simon Ilg
-
Patent number: 9284532Abstract: The present invention relates to mammalian cells capable of propagating Arterivirus, to such cells infected with Arterivirus, to cell cultures comprising such cells and to methods for the propagation of an Arterivirus in such cells.Type: GrantFiled: December 17, 2013Date of Patent: March 15, 2016Assignee: Intervet Inc.Inventors: Lars Guelen, Carla Christina Schrier
-
Patent number: 9198963Abstract: The present invention pertains to the use of a non-live carbohydrate containing composition, the carbohydrate being also found in live Lawsonia intracellularis cells in association with the outer cell membrane of these cells, for the manufacture of a vaccine for protection against an infection with Lawsonia intracellularis, the vaccine being in a form suitable for systemic administration.Type: GrantFiled: July 17, 2013Date of Patent: December 1, 2015Assignee: Intervet International B.V.Inventors: Antonius Arnoldus Christiaan Jacobs, Paul Vermeij, Ruud Philip Antoon Maria Segers, Carla Christina Schrier